158 related articles for article (PubMed ID: 32902984)
1. Discovery of 9-Cyclopropylethynyl-2-((
Labéguère F; Dupont S; Alvey L; Soulas F; Newsome G; Tirera A; Quenehen V; Mai TTT; Deprez P; Blanqué R; Oste L; Le Tallec S; De Vos S; Hagers A; Vandevelde A; Nelles L; Vandervoort N; Conrath K; Christophe T; van der Aar E; Wakselman E; Merciris D; Cottereaux C; da Costa C; Saniere L; Clement-Lacroix P; Jenkins L; Milligan G; Fletcher S; Brys R; Gosmini R
J Med Chem; 2020 Nov; 63(22):13526-13545. PubMed ID: 32902984
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the G-Protein-Coupled Receptor 84 (GPR84) by Agonists and Antagonists.
Chen LH; Zhang Q; Xie X; Nan FJ
J Med Chem; 2020 Dec; 63(24):15399-15409. PubMed ID: 33267584
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease.
Simard JC; Thibodeau JF; Leduc M; Tremblay M; Laverdure A; Sarra-Bournet F; Gagnon W; Ouboudinar J; Gervais L; Felton A; Letourneau S; Geerts L; Cloutier MP; Hince K; Corpuz R; Blais A; Quintela VM; Duceppe JS; Abbott SD; Blais A; Zacharie B; Laurin P; Laplante SR; Kennedy CRJ; Hébert RL; Leblond FA; Grouix B; Gagnon L
Sci Rep; 2020 Jul; 10(1):12778. PubMed ID: 32728158
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesters as GPR84 Antagonists for the Treatment of Ulcerative Colitis.
Chen LH; Zhang Q; Xiao YF; Fang YC; Xie X; Nan FJ
J Med Chem; 2022 Mar; 65(5):3991-4006. PubMed ID: 35195005
[TBL] [Abstract][Full Text] [Related]
5. GLPG1205, a GPR84 Modulator: Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects.
Timmis H; Van Kaem T; Desrivot J; Dupont S; Meuleners L; Beetens J; Helmer E; Santermans E; Huettner S
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):994-1006. PubMed ID: 33960725
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Characterization of a Novel Small-Molecule Agonist for Medium-Chain Free Fatty Acid Receptor G Protein-Coupled Receptor 84.
Zhang Q; Yang H; Li J; Xie X
J Pharmacol Exp Ther; 2016 May; 357(2):337-44. PubMed ID: 26962172
[TBL] [Abstract][Full Text] [Related]
7. Similarities and differences between the responses induced in human phagocytes through activation of the medium chain fatty acid receptor GPR84 and the short chain fatty acid receptor FFA2R.
Sundqvist M; Christenson K; Holdfeldt A; Gabl M; Mårtensson J; Björkman L; Dieckmann R; Dahlgren C; Forsman H
Biochim Biophys Acta Mol Cell Res; 2018 May; 1865(5):695-708. PubMed ID: 29477577
[TBL] [Abstract][Full Text] [Related]
8. A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84.
Gagnon L; Leduc M; Thibodeau JF; Zhang MZ; Grouix B; Sarra-Bournet F; Gagnon W; Hince K; Tremblay M; Geerts L; Kennedy CRJ; Hébert RL; Gutsol A; Holterman CE; Kamto E; Gervais L; Ouboudinar J; Richard J; Felton A; Laverdure A; Simard JC; Létourneau S; Cloutier MP; Leblond FA; Abbott SD; Penney C; Duceppe JS; Zacharie B; Dupuis J; Calderone A; Nguyen QT; Harris RC; Laurin P
Am J Pathol; 2018 May; 188(5):1132-1148. PubMed ID: 29454750
[TBL] [Abstract][Full Text] [Related]
9. Agonists for G-protein-coupled receptor 84 (GPR84) alter cellular morphology and motility but do not induce pro-inflammatory responses in microglia.
Wei L; Tokizane K; Konishi H; Yu HR; Kiyama H
J Neuroinflammation; 2017 Oct; 14(1):198. PubMed ID: 28974234
[TBL] [Abstract][Full Text] [Related]
10. Strategies for the identification of allosteric modulators of G-protein-coupled receptors.
Burford NT; Watson J; Bertekap R; Alt A
Biochem Pharmacol; 2011 Mar; 81(6):691-702. PubMed ID: 21184747
[TBL] [Abstract][Full Text] [Related]
11. Investigating the Structure-Activity Relationship of 1,2,4-Triazine G-Protein-Coupled Receptor 84 (GPR84) Antagonists.
Mahindra A; Jenkins L; Marsango S; Huggett M; Huggett M; Robinson L; Gillespie J; Rajamanickam M; Morrison A; McElroy S; Tikhonova IG; Milligan G; Jamieson AG
J Med Chem; 2022 Aug; 65(16):11270-11290. PubMed ID: 35948061
[TBL] [Abstract][Full Text] [Related]
12. Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator.
Zhang L; Balan G; Barreiro G; Boscoe BP; Chenard LK; Cianfrogna J; Claffey MM; Chen L; Coffman KJ; Drozda SE; Dunetz JR; Fonseca KR; Galatsis P; Grimwood S; Lazzaro JT; Mancuso JY; Miller EL; Reese MR; Rogers BN; Sakurada I; Skaddan M; Smith DL; Stepan AF; Trapa P; Tuttle JB; Verhoest PR; Walker DP; Wright AS; Zaleska MM; Zasadny K; Shaffer CL
J Med Chem; 2014 Feb; 57(3):861-77. PubMed ID: 24392688
[TBL] [Abstract][Full Text] [Related]
13. Embelin and its derivatives unravel the signaling, proinflammatory and antiatherogenic properties of GPR84 receptor.
Gaidarov I; Anthony T; Gatlin J; Chen X; Mills D; Solomon M; Han S; Semple G; Unett DJ
Pharmacol Res; 2018 May; 131():185-198. PubMed ID: 29471103
[TBL] [Abstract][Full Text] [Related]
14. Mutation analysis and molecular modeling for the investigation of ligand-binding modes of GPR84.
Nikaido Y; Koyama Y; Yoshikawa Y; Furuya T; Takeda S
J Biochem; 2015 May; 157(5):311-20. PubMed ID: 25425658
[TBL] [Abstract][Full Text] [Related]
15. PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure.
Nguyen QT; Nsaibia MJ; Sirois MG; Calderone A; Tardif JC; Fen Shi Y; Ruiz M; Daneault C; Gagnon L; Grouix B; Laurin P; Dupuis J
Cardiovasc Res; 2020 Jan; 116(1):171-182. PubMed ID: 30753422
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates.
Stepan AF; Claffey MM; Reese MR; Balan G; Barreiro G; Barricklow J; Bohanon MJ; Boscoe BP; Cappon GD; Chenard LK; Cianfrogna J; Chen L; Coffman KJ; Drozda SE; Dunetz JR; Ghosh S; Hou X; Houle C; Karki K; Lazzaro JT; Mancuso JY; Marcek JM; Miller EL; Moen MA; O'Neil S; Sakurada I; Skaddan M; Parikh V; Smith DL; Trapa P; Tuttle JB; Verhoest PR; Walker DP; Won A; Wright AS; Whritenour J; Zasadny K; Zaleska MM; Zhang L; Shaffer CL
J Med Chem; 2017 Sep; 60(18):7764-7780. PubMed ID: 28817277
[TBL] [Abstract][Full Text] [Related]
17. Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile).
Christopher JA; Aves SJ; Bennett KA; Doré AS; Errey JC; Jazayeri A; Marshall FH; Okrasa K; Serrano-Vega MJ; Tehan BG; Wiggin GR; Congreve M
J Med Chem; 2015 Aug; 58(16):6653-64. PubMed ID: 26225459
[TBL] [Abstract][Full Text] [Related]
18. Functional selectivity in GPCR modulator screening.
Kenakin T
Comb Chem High Throughput Screen; 2008 Jun; 11(5):337-43. PubMed ID: 18537555
[TBL] [Abstract][Full Text] [Related]
19. Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists.
Fujimoto T; Kunitomo J; Tomata Y; Nishiyama K; Nakashima M; Hirozane M; Yoshikubo S; Hirai K; Marui S
Bioorg Med Chem Lett; 2011 Nov; 21(21):6414-6. PubMed ID: 21917455
[TBL] [Abstract][Full Text] [Related]
20. G protein-coupled receptor 84 controls osteoclastogenesis through inhibition of NF-κB and MAPK signaling pathways.
Park JW; Yoon HJ; Kang WY; Cho S; Seong SJ; Lee HW; Yoon YR; Kim HJ
J Cell Physiol; 2018 Feb; 233(2):1481-1489. PubMed ID: 28574596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
